76
A. Shaabani et al.: 3-Aminoimidazo[1,2-a]pyridines and -pyrazines
(s, OCH3), 3.80–3.90 (bs, NH), 6.95–8.96 (m, H–Ar) ppm; 13C NMR (CDCl3): ꢂ ¼ 24.88, 25.33,
34.11 (C–cyclohexyl), 55.34 (OCH3), 56.23 (CH–N–cyclohexyl), 114.24, 117.73, 123.59, 126.74,
128.61, 129.05, 134.61, 139.61, 140.86, 160.51 (C–Ar) ppm.
N-tert-Butyl-2-(4-methoxyphenyl)imidazo[1,2-a]pyrazin-3-amine (4k, C17H20N4O)
Yellow crystals (0.25 g, 85%); mp 165–168ꢁC (dec); IR (KBr): ꢁꢀ ¼ 3275, 2850, 1644, 1606cmꢂ1
;
1
MS: m=z (%) ¼ 296 (Mþ þ 1, 19), 295 (Mþ, 32), 209 (100), 92 (67), 65 (34), 57 (23); H NMR
(DMSO-d6): ꢂ ¼ 1.04 (s, C(CH3)3), 3.79 (s, OCH3), 3.84 (bs, NH), 6.89 (d, J ¼ 8.6 Hz, H–Ar), 7.94
(d, J ¼ 8.6Hz, H–Ar), 7.99–9.17 (m, H–Ar) ppm; 13C NMR (DMSO-d6): ꢂ ¼ 30.34 (C(CH3)3), 55.26
(C(CH3)3), 57.27 (OCH3), 113.95, 117.44, 123.30, 126.45, 128.33, 129.69, 134.32, 139.32 140.58,
160.26 (C–Ar) ppm.
Acknowledgement
We gratefully acknowledge the financial support from the Research Council of Shahid Beheshti
University.
References
[1] a) Maruyama Y, Anami K, Terasawa M, Goto, K, Imayoshi T, Kadobe Y, Mizushima Y (1981)
Arzneimittel-Forsch 31: 1111; b) Maruyama Y, Anami K, Katoh Y (1978) Arzneimittel-Forsch
28: 2102
[2] Rival Y, Grassy G, Michel G (1992) Chem Pharm Bull 40: 1170
[3] Kaminski JJ, Wallmark B, Briving C, Andersson BM (1991) J Med Chem 34: 533
[4] Sanfilippo PJ, Urbanski M, Press JB, Dubinsky B, Moore JB (1988) J Med Chem 31: 2221
[5] Trapani G, Franco M, Ricciardi L, Latrofa A, Genchi G, Sanna E, Tuveri F, Cagetti E, Biggio G,
Liso G (1997) J Med Chem 40: 3109
[6] a) Sablayrolles C, Cros GH, Milhavet JC, Rechenq E, Chapat JP, Boucard M, Serrano JJ, McNeill
JH (1984) J Med Chem 27: 206; b) Spitzer WA, Victor F, Pollock DG, Hayers JS (1988) J Med
Chem 31: 1590; c) Blewitt HL (1977) In: Weissberger A, Taylor EC (eds) Special Topics in
Heterocyclic Chemistry. Wiley, New York, p 117
[7] a) Blackburn C, Guan B, Fleming P, Shiosaki K, Tsai S (1998) Tetrahedron Lett 39: 3635;
b) Bienayme H, Bouzid K (1998) Angew Chem Int Ed 37: 2234; c) Groebke K, Weber L, Mehlin
F (1998) Synlett 661; d) Blackburn C (1998) Tetrahedron Lett 39: 5469; d) Mandair GS, Light M,
Russell A, Hursthouse M, Bradley M (2002) Tetrahedron Lett 43: 4267
[8] Varma RS, Kumar D (1999) Tetrahedron Lett 40: 7665
[9] Ireland SM, Tye H, Whittaker M (2003) Tetrahedron Lett 44: 4369
[10] Zolfigol MA (2001) Tetrahedron 57: 9509
[11] a) Shaabani A, Bazgir A, Teimouri F, Lee DG (2002) Tetrahedron Lett 43: 5165; b) Shaabani
A, Soleimani K, Bazgir A (2004) Synth Commun 34: 3303; c) Shaabani A, Teimouri F, Lee
DG (2003) Synth Commun 33: 1057; d) Shaabani A, Lee DG (2003) Synth Commun 33:
1255
[12] a) Shaabani A, Soleimani E, Khavasi HR, Hoffmann RD, Rodewald UC, Poettgen R (2006)
Tetrahedron Lett 47: 5493; b) Shaabani A, Teimouri MB, Arab Ameri S (2004) Tetrahedron Lett
45: 8409; c) Shaabani A, Teimouri MB, Bijanzadeh HR (2002) Tetrahedron Lett 43: 9151;
d) Shaabani A, Yavari I, Teimouri MB, Bazgir A, Bijanzadeh HR (2001) Tetrahedron 57: 1375;
e) Shaabani A, Teimouri MB, Bazgir A, Bijanzadeh HR (2003) Mol Div 6: 199; f) Shaabani A,
Teimouri MB, Bijanzadeh HR (2004) Monatsh Chem 135: 441; g) Shaabani A, Soleimani E,
Maleki A (2006) Tetrahedron Lett 47: 3031; h) Shaabani A, Teimouri MB, Bijanzadeh HR
(2003) J Chem Res (S) 578